---
title: "BNR: Stable volumes and strong pricing drove margin gains, with cost savings accelerating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295677284.md"
description: "Volumes remained stable year-over-year in Q2 2026, with strong pricing and cost savings driving margin improvements. Working capital peaked due to higher prices, but efficiency gains and structural initiatives are expected to support ongoing performance.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T14:04:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295677284.md)
  - [en](https://longbridge.com/en/news/295677284.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295677284.md)
generator: "portal-rs"
---

# BNR: Stable volumes and strong pricing drove margin gains, with cost savings accelerating

Volumes remained stable year-over-year in Q2 2026, with strong pricing and cost savings driving margin improvements. Working capital peaked due to higher prices, but efficiency gains and structural initiatives are expected to support ongoing performance.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [BNR.US](https://longbridge.com/en/quote/BNR.US.md)

## Related News & Research

- [BNR: Sequential revenue growth and margin gains offset year-over-year declines, led by in-hospital expansion](https://longbridge.com/en/news/298591745.md)
- [Burning Rock Biotech Q3 non-GAAP EPS of RMB -$0.17, revenue of RMB $134.77M](https://longbridge.com/en/news/298615146.md)
- [Burning Rock MRD kit enters China NMPA innovative device fast-track review](https://longbridge.com/en/news/298472255.md)
- [13:15 ETAshland University and Ed3 Partner to Bring Pedagogy-First AI Literacy Training to Ohio Educators](https://longbridge.com/en/news/298350777.md)
- [QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy](https://longbridge.com/en/news/298366322.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**